ClinicalTrials.gg
Active, not recruitingNCT04629729Updated Mar 19, 2026

FT819 in Subjects With B-cell Malignancies

A Phase 1 interventional study of FT819 and Cyclophosphamide in Lymphoma, B-Cell, Chronic Lymphocytic Leukemia and Precursor B-Cell Acute Lymphoblastic Leukemia, sponsored by Fate Therapeutics. Active, not recruiting at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Fate Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 398 studies in Lymphoma, B-Cell with a site in United States — 90 open to participants now, 156 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Enrollment
132nd of 380
54 · median 37
Started
2021
with 30 others
Phase 1
161 of 398
34 open now
Primary completion
2025-06
later than 21 of 155 live
Registered
250th of 398
by date

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 132nd largest by enrollment of the 380 interventional ones that give a count, is one of 31 that started in 2021, is one of 161 in phase 1, reaches primary completion later than 21 of the 155 other live ones, and was the 250th registered.

Lymphoma, B-Cell

886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

90 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

03

Conditions studied

  • Lymphoma, B-Cell
  • Chronic Lymphocytic Leukemia
  • Precursor B-Cell Acute Lymphoblastic Leukemia

Keywords

  • Lymphoma
  • Leukemia
  • BCL
  • CLL
  • B-ALL
  • CAR-T
  • cellular therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Diagnosis of B-cell lymphoma, CLL or B-ALL as described below:

B-Cell Lymphoma:

  • documented lymphomas expected to express CD19
  • disease following at least 2 prior lines of multi-agent immunochemotherapy

Chronic Lymphocytic Leukemia (CLL):

  • Diagnosis of CLL per iwCLL guidelines
  • Relapsed/refractory disease following at least two prior systemic treatment regimens

Precursor B-cell Acute Lymphocytic Leukemia (B-ALL):

  • Diagnosis of B-ALL by flow cytometry, bone marrow histology, and/or cytogenetics
  • Relapsed/refractory disease after at least 2 cycles of standard multiagent induction chemotherapy. For subjects with Philadelphia-chromosome positive (Ph+) disease, failure or intolerance to a tyrosine kinase inhibitor therapy-containing regimen

ALL SUBJECTS:

  • Capable of giving signed
  • Age ≥ 18 years old
  • Stated willingness to comply with study procedures and duration
  • use for women and men as defined in the protocol

Key Exclusion Criteria:

ALL SUBJECTS:

  • Females who are pregnant or breastfeeding
  • (ECOG) Performance Status ≥2
  • Body weight \<50 kg
  • Evidence of insufficient organ function
  • Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any therapy within 28 days prior to Day 1
  • Currently receiving or likely to require systemic therapy
  • Ongoing requirement for systemic GvHD therapy following prior hematopoietic stem cell transplant (HSCT) or allogeneic CAR-T
  • Receipt of an allograft organ transplant
  • Known active central nervous system (CNS) involvement by
  • Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
  • cardiovascular disease
  • Positive serologic test results for infection
  • Positive serologic and polymerase chain reaction (PCR) test results for (HBV) infection
  • Positive serologic and PCR test results for (HCV) infection
  • \<6 weeks prior to start of lympho-conditioning
  • Known allergy to albumin (human) or DMSO
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    FT819 Single-Dose Monotherapy, B-Cell Lymphoma

    FT819 single-dose monotherapy in adult subjects with r/r B-cell Lymphoma

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

  • Experimental
    FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma

    FT819 single-dose in combination with IL-2 in adult subjects with r/r B-cell Lymphoma

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: IL-2 · Drug: Bendamustine

  • Experimental
    FT819 Step Fractionated Monotherapy, B-Cell Lymphoma

    FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-cell Lymphoma

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

  • Experimental
    FT819 Single-Dose Monotherapy, CLL

    FT819 single-dose monotherapy in adult subjects with r/r CLL

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

  • Experimental
    FT819 Single-Dose in Combination with IL-2, CLL

    FT819 single-dose in combination with IL-2 in adult subjects with r/r CLL

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: IL-2 · Drug: Bendamustine

  • Experimental
    FT819 Step Fractionated Monotherapy, CLL

    FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r CLL

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

  • Experimental
    FT819 Single-Dose Monotherapy, B-ALL

    FT819 single-dose monotherapy in adult subjects with r/r B-ALL

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

  • Experimental
    FT819 Single-Dose in Combination with IL-2, B-ALL

    FT819 single-dose in combination with IL-2 in adult subjects with r/r B-ALL

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: IL-2 · Drug: Bendamustine

  • Experimental
    FT819 Step Fractionated Monotherapy, B-ALL

    FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-ALL

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Bendamustine

  • Experimental
    FT819 Step Fractionated Monotherapy in Combination with IL-2, B-Cell Lymphoma

    FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r B-cell Lymphoma

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: IL-2 · Drug: Bendamustine

  • Experimental
    FT819 Step Fractionated Monotherapy in Combination with IL-2, CLL

    FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r CLL

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: IL-2 · Drug: Bendamustine

  • Experimental
    FT819 Step Fractionated Monotherapy in Combination with IL-2, B-ALL

    FT819 monotherapy administered as step-fractionated dosing in combination with IL-2 in adult subjects with r/r B-ALL

    Drug: FT819 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: IL-2 · Drug: Bendamustine

Interventions

  • DrugFT819

    Experimental Interventional Therapy

  • Lympho-conditioning agent

  • Lympho-conditioning agent

    Also known as: Fludara

  • DrugIL-2

    Biologic response modifier

    Also known as: Interleukin-2

  • Lympho-conditioning agent

    Also known as: Bendeka, Treanda

06

What researchers measure

Primary outcomes

  1. Incidence and nature of dose-limiting toxicities within each dose level cohort

    Time frame: Up to Day 29

  2. Incidence, nature, and severity of adverse events (AEs) of FT819 as monotherapy and in combination with IL-2 in r/r B-cell lymphoma, r/r chronic lymphocytic leukemia, and r/r precursor B-cell acute lymphoblastic leukemia

    Time frame: Up to 15 years

Secondary outcomes

  1. Investigator-assessed objective-response rate (ORR)

    Time frame: Up to approximately 2 years after last dose of FT819

  2. For BCL and CLL Only: Investigator-assessed duration of objective response (DOR)

    Time frame: Up to 15 years

  3. For BCL and CLL Only: Investigator-assessed duration of complete response (DoCR)

    Time frame: Up to 15 years

  4. For BCL and CLL Only: Progression-free survival (PFS)

    Time frame: Up to 15 years

  5. Overall survival (OS)

    Time frame: Up to 15 years

  6. Determination of the pharmacokinetics of FT819 cells in peripheral blood.

    The PK of FT819 in peripheral blood will be reported as the relative percentage of product (FT819) DNA versus patient DNA (% chimerism) measured from blood samples at the specified time points

    Time frame: Study Days 1, 2, 3, 4, 5, 8, 11, 15, 22, and 29

  7. For B-ALL Only: Investigator-assessed relapse-free survival (RFS)

    Time frame: Up to 15 years

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jun 2025, 47 months.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's 47 months is close to that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2020
First posted
Nov 16, 2020
StartActual
Jul 12, 2021
Primary completionActual
Jun 18, 2025
CompletionEst.
Sep 30, 2039
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04629729
Lead sponsor
Fate Therapeutics
Responsible party
Sponsor
First posted
Nov 16, 2020
Start date
Jul 12, 2021
Primary completion
Jun 18, 2025
Completion
Sep 30, 2039 (estimated)
Last update
Mar 19, 2026

Study contacts

Fate Trial Disclosure
study director · Fate Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: iPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819

Start the discussion